Table 3 Prognostic factors associated with OS and PFS in univariate analysis

Gender, male/female

0.986

1.009 (0.384–2.651)

0.579

1.197 (0.635–2.254)

Age, ≥60/<60

0.109

2.142 (0.844–5.440)

0.007*

0.397 (0.203–0.775)

Number of metastasis, ≥3/<3

0.049*

1.323 (1.011–1.809)

0.015*

2.167 (1.159–4.054)

Liver metastasis resection, yes/no

0.001*

0.028 (0.012–0.049)

0.005*

0.313 (0.138–0.710)

Chemotherapy, FOLFOX/XELOX

0.735

0.855 (0.346–2.113)

0.891

0.925 (0.522–1.759)

Maximum size (cm), ≤4/>4

0.261

2.385 (0.525–10.84)

0.620

1.164 (0.638–2.123)

Pathology, adenocarcinoma/mucinous

0.261

2.385 (0.525–10.84)

0.737

1.225 (0.376–3.993)

Differentiation, G1–G2/G3–G4

0.930

0.958 (0.371–2.478)

0.302

1.386 (0.745–2.580)

Location, colon/rectum

0.421

1.159 (0.809–1.659)

0.446

1.265 (0.691–2.314)

 T2/T3

0.835

6.231 (0.926–52.51)

0.054

7.826 (0.962–63.66)

 T2/T4

0.554

1.339 (0.460–4.251)

0.094

2.410 (0.899–4.843)

 N0/N1

0.496

0.637 (0.174–2.330)

0.811

0.908 (0.412–2.001)

 N0/N2

0.759

0.859 (0.326–2.265)

0.396

0.396 (0.369–1.483)

Lymphovascular invasion, no/yes

0.399

0.683 (0.281–1.658)

0.867

0.950 (0.520–1.735)

Perineural invasion, no/yes

0.289

1.613 (0.667–3.899)

0.064

1.775 (0.967–30257)

Extranodal tumor deposits, no/yes

0.340

1.542 (0.633–3.755)

0.549

1.201 (0.660–2.186)

MSI status, pMMR/MMR

0.371

0.606 (0.202–1.817)

0.542

0.673 (0.189–2.404)

NLR, ≥4/<4

0.013*

3.182 (1.277–7.933)

0.017*

2.284 (1.156–4.498)

PLR, ≥150/<150

0.024*

2.954 (1.155–7.551)

0.002*

2.535 (1.339–4.779)

ALP, elevated/normal

0.905

0.927 (0.267–3.217)

0.374

1.449 (0.640–3.282)

LDH, elevated/normal

0.257

1.810 (0.650–5.041)

0.008

2.673 (1.292–5.528)

Serum CA199 level, elevated/normal

0.343

1.640 (0.590–4.560)

0.700

1.135 (0.596–2.158)

Serum CEA level, elevated/normal

0.487

1.552 (0.450–5.351)

0.669

1.183 (0.548–2.553)